Health anxiety: Current perspectives and future directions

Current Psychiatry Reports

Volumn 12, Issue 4, 2010, Pages 306-312

  Asmundson, Gordon J G ^a   Abramowitz, Jonathon S ^b   Richter, Ashley A ^a   Whedon, Margaret ^b  

^a UNIVERSITY OF REGINA   (Canada)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

Cognitive; Health anxiety; Hypochondriasis; Review; Treatment

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ANXIETY DISORDER; ATTITUDE TO HEALTH; AVERSIVE BEHAVIOR; CLINICAL TRIAL; COGNITIVE BEHAVIORAL STRESS MANAGEMENT; COGNITIVE THERAPY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; EMOTIONAL DISORDER; EXPOSURE AND RESPONSE PREVENTION; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; HEALTH BELIEF; HERITABILITY; HUMAN; HYPOCHONDRIASIS; INTERMETHOD COMPARISON; LONG TERM EXPOSURE; MENTAL HEALTH; OBSESSIVE COMPULSIVE DISORDER; PANIC; PERSONALITY DISORDER; PHOBIA; PREVENTION STUDY; PSYCHOEDUCATION; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOTHERAPY; RELAPSE; REVIEW; RISK FACTOR; SOMATIC DELUSION; THERAPY EFFECT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VULNERABLE POPULATION; ANXIETY DISORDERS; CLASSIFICATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HEALTH STATUS;

ANXIETY DISORDERS; ATTITUDE TO HEALTH; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HEALTH STATUS; HUMANS; HYPOCHONDRIASIS;

EID: 77956386350     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-010-0123-9     Document Type: Review

References (44)

1. Salkovskis PM, Warwick HMC: Morbid preoccupations, health anxiety and reassurance: A cognitive-behavioral approach to hypochondriasis. Behav Res Ther 1986, 24:597-602.
2. Taylor S, Asmundson GJG: Treating Health Anxiety: A Cognitive-Behavioral Approach. New York: Guilford; 2004.
3. Barsky AJ, Klerman GL: Overview: Hypochondriasis, bodily complaints, and somatic styles. Am J Psychiatry 1983, 140:273-283.
4. Haenen MA, de Jong PJ, Schmidt AJM, et al.: Hypochondriacs' estimation of negative outcomes: Domain-specificity and responsiveness to reassuring and alarming information. Behav Res Ther 2000, 38:819-833.
5. Warwick HM, Salkovskis PM: Hypochondriasis. Behav Res Ther 1990, 28:105-117.
6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4 (text revision). Washington, DC: American Psychiatric Association; 2000.
7. Collimore KC, Asmundson GJG, Taylor S, et al.: Classification of hypochondriasis and other somatoform disorders. In Current Perspectives on the Anxiety Disorders: Implications for DSM-V and Beyond. Edited by McKay D, Abramowitz JS, Taylor S, Asmundson GJG. New York: Springer; 2009:431-452. This recent book chapter provides a comprehensive overview of current perspectives on classification considerations and options for hypochondriasis as we move toward the DSM-V.
8. Taylor S, Asmundson GJG, Abramowitz JS, et al.: Classification of anxiety disorders for DSM-V and ICD-11: Issues, proposals, and controversies. In Current Perspectives on the Anxiety Disorders: Implications for DSM-V and Beyond. Edited by McKay D, Abramowitz JS, Taylor S, Asmundson GJG. New York: Springer; 2009:481-511.
9. Tyrer P, Fowler-Dixon R, Ferguson B, et al.: A plea for the diagnosis of hypochondriacal personality disorder. J Psychosom Res 1990, 34:637-642.
10. Deacon B, Abramowitz J: Is hypochondriasis related to obsessive-compulsive disorder, panic disorder, or both? An empirical evaluation. J Cogn Psychother 2008, 22:115-127. This recent investigation demonstrates that although some overlap exists among hypochondriasis, OCD, and panic disorder in symptoms and dysfunctional beliefs, the former is typified by health anxiety and dysfunctional beliefs regarding somatic sensations.
11. Ferguson E: A taxometric analysis of health anxiety. Psychol Med 2009, 39:277-285. This recent investigation is the first to empirically confirm, using common taxometric procedures, suggestions that latent structure of health anxiety is a continuous rather than categorical construct.
12. Pilowsky I: Dimensions of hypochondriasis. Br J Psychiatry 1967, 113:89-93.
13. Olatunji B: Incremental specificity of disgust propensity and sensitivity in the prediction of health anxiety dimensions. J Behav Ther Exp Psychiatry 2009, 40:230-239. This recent investigation adds to our understanding of potential etiologic and maintenance mechanisms of severe health anxiety by demonstrating the importance of disgust propensity to overestimates of disease likelihood, disease severity, and somatic focus.
14. Abramowitz JS, Braddock AE: Psychological Treatment of Health Anxiety and Hypochondriasis: A Biopsychosocial Approach. Göttingen, Germany: Hogrefe & Huber; 2008.
15. Karademas E: Effects of exposure to the suffering of unknown persons on health-related cognitions, and the role of mood. Health (London) 2009, 13:491-504. This recent investigation is the first to systematically evaluate and confirm the tenet of cognitivebehavioral models that exposure to health-related suffering of an unknown person influences one's own health anxiety.
16. Taylor S: Understanding and Treating Panic Disorder: Cognitive- Behavioural Approaches. New York: Wiley; 2000.
17. Olatunji B, Wolitzky-Taylor K, Elwood L, et al.: Anxiety sensitivity and health anxiety in a nonclinical sample: Specificity and prospective relations with clinical stress. Cognit Ther Res 2009, 33:416-424.
18. Stein MB, Jang KL, Livesley WJ: Heritability of anxiety sensitivity: A twin study. Am J Psychiatry 1999, 156:246-251.
19. Taylor S, Thordarson DS, Jang KL, et al.: Genetic and environmental origins of health anxiety: A twin study. World Psychiatry 2006, 5:47-50.
20. Taylor S, Jang K, Stein M, et al.: A behavioral-genetic analysis of health anxiety: Implications for the cognitive-behavioral model of hypochondriasis. J Cogn Psychother 2008, 22:143-153. This is the most recent of our behavior genetics investigations of health anxiety. The investigation suggests that after controlling for medical morbidity, the features of health anxiety (ie, disease conviction, fear of disease, interference) are influenced by a common set of genes and feature specific environmental influences.
21. Pilowsky I, Spence N: Manual for the Illness Behaviour Questionnaire, edn 3. Adelaide, Australia: Department of Psychiatry, University of Adelaide; 1994.
22. Salkovskis PM, Rimes KA, Warwick HM, et al.: The Health Anxiety Inventory: Development and validation of scales for the measurement of health anxiety and hypochondriasis. Psychol Med 2002, 32:843-853.
23. Goodman WK, Price LH, Rasmussen SA, et al.: The Yale-Brown Obsessive Compulsive Scale: Development, use, and reliability. Arch Gen Psychiatry 1989, 46:1006-1011.
24. Goodman WK, Price LH, Rasmussen SA, et al.: The Yale-Brown Obsessive Compulsive Scale: Validity. Arch Gen Psychiatry 1989, 46:1012-1016.
25. Greeven A, Spinhoven P, Balkom A: Hypochondriasis Y-BOCS: A study of the psychometric properties of a clinician-administered semi-structured interview to assess hypochondriacal thoughts and behaviors. Clin Psychol Psychother 2009, 16:431-443. This is the first study to systematically evaluate the psychometric properties of a clinician-administered interview for various features of health anxiety. Although only some aspects of the interview demonstrated acceptable psychometric properties, the interview has potential for clinical and research utility.
26. Taylor S, Asmundson GJG, Coons MJ: Current directions in the treatment of hypochondriasis. J Cogn Psychother 2005, 19:291-310.
27. Buwalda FM, Bouman TK, Van Duijn MAJ: The effect of a psychoeducational course on hypochondriacal metacognition. Cognit Ther Res 2008, 32:689-701.
28. Avia MD, Ruiz MA, Olivares ME, et al.: The meaning of psychological symptoms: Effectiveness of a group intervention with hypochondriacal patients. Behav Res Ther 1996, 34:23-31.
29. Bouman TK: A community-based psychoeducational group approach to hypochondriasis. Psychother Psychosom 2002, 71:326-332.
30. Lidbeck J: Group therapy for somatization disorders in general practice: Effectiveness of a short cognitive-behavioral treatment model. Acta Psychiatr Scand 1997, 96:14-24.
31. Logsdail S, Lovell K, Warwick HM, et al.: Behavioral treatment of AIDS-focused illness phobia. Br J Psychiatry 1991, 159:422-425.
32. Visser S, Bouman TK: Cognitive-behavioral approaches in the treatment of hypochondriasis: Six single case cross-over studies. Behav Res Ther 1992, 30:301-306.
33. Visser S, Bouman TK: The treatment of hypochondriasis: Exposure plus response prevention versus cognitive therapy. Behav Res Ther 2001, 39:423-442.
34. Clark DM, Salkovskis PM, Hackmann A, et al.: Two psychological treatments for hypochondriasis: A randomised controlled trial. Br J Psychiatry 1998, 173:218-225.
35. Martinez MP, Botella C: An exploratory study of the efficacy of a cognitive-behavioral treatment for hypochondriasis using different measures of change. Psychother Res 2005, 15:392-408.
36. Stern R, Fernandez M: Group cognitive and behavioral treatment for hypochondriasis. BMJ 1991, 303:1229-1231.
37. Barsky AJ, Ahern DK: Cognitive behavior therapy for hypochondriasis: A randomized controlled trial. JAMA 2004, 291:1464-1470.
38. Warwick HM, Clark DM, Cobb AM, et al.: A controlled-trial of cognitive-behavioral treatment of hypochondriasis. Br J Psychiatry 1996, 169:189-195.
39. Fallon BA: Pharmacologic strategies for hypochondriasis. In Hypochondriasis: Modern Perspectives on an Ancient Malady. Edited by Starcevic V, Lipsett DR. New York: Oxford University Press; 2001:329-351.
40. Wesner RB, Noyes R: Imipramine: An effective treatment for illness phobia. J Affect Disord 1991, 22:43-48.
41. Fallon BA, Schneier FR, Marshall R, et al.: The pharmacotherapy of hypochondriasis. Psychopharmacol Bull 1996, 32:607-611.
42. Fallon BA: Pharmacotherapy of hypochondriasis. Paper presented at the International Congress on Somatoform Disorders. Marburg, Germany; February 2002.
43. Walker J, Vincent N, Furer P, et al.: Treatment preference in hypochondriasis. J Behav Ther Exp Psychiatry 1999, 30:251-258.
44. Oosterbaan DB, van Balkom AJLM, van Boeijen CA, et al.: An open study of paroxetine in hypochondriasis. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:1023-1033.